Tags

Type your tag names separated by a space and hit enter

Silymarin in non alcoholic fatty liver disease.
World J Hepatol 2013; 5(3):109-13WJ

Abstract

AIM

This study was undertaken to evaluate the hepatic effects of silybum marianum on non alcoholic fatty liver disease (NAFLD).

METHODS

In 72 patients affected by NAFLD, main metabolic, hepatic and anti-inflammatory parameters were assayed after 3 mo of a restricted diet and before silymarin treatment (twice a day orally). The brightness of liver echography texture (hepatorenal ratio brightness) was also defined at same time. These evaluations were repeated after 6 mo of treatment.

RESULTS

Serum levels of some metabolic and anti-inflammatory data nonsignificantly lowered after 6 mo of silymarin. On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase were significantly (P < 0.001) reduced. Instead, the AST/ALT ratio unchanged. Finally, the hepatorenal brightness ratio, as an index of hepatic steatosis, significantly (P < 0.05) dropped.

CONCLUSION

The obtained results indicate that silymarin appears to be effective to reduce the biochemical, inflammatory and ultrasonic indices of hepatic steatosis. Some parameters indicative of early stage of atherosclerosis were also lowered.

Authors+Show Affiliations

Fulvio Cacciapuoti, Anna Scognamiglio, Rossella Palumbo, Raffaele Forte, Federico Cacciapuoti, Department of Internal Medicine and Geriatrics, Second University of Naples, 80138 Naples, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23556042

Citation

Cacciapuoti, Fulvio, et al. "Silymarin in Non Alcoholic Fatty Liver Disease." World Journal of Hepatology, vol. 5, no. 3, 2013, pp. 109-13.
Cacciapuoti F, Scognamiglio A, Palumbo R, et al. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013;5(3):109-13.
Cacciapuoti, F., Scognamiglio, A., Palumbo, R., Forte, R., & Cacciapuoti, F. (2013). Silymarin in non alcoholic fatty liver disease. World Journal of Hepatology, 5(3), pp. 109-13. doi:10.4254/wjh.v5.i3.109.
Cacciapuoti F, et al. Silymarin in Non Alcoholic Fatty Liver Disease. World J Hepatol. 2013 Mar 27;5(3):109-13. PubMed PMID: 23556042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Silymarin in non alcoholic fatty liver disease. AU - Cacciapuoti,Fulvio, AU - Scognamiglio,Anna, AU - Palumbo,Rossella, AU - Forte,Raffaele, AU - Cacciapuoti,Federico, PY - 2012/05/13/received PY - 2012/09/24/revised PY - 2012/11/14/accepted PY - 2013/4/5/entrez PY - 2013/4/5/pubmed PY - 2013/4/5/medline KW - Alanine aminotransferase KW - Aspartate aminotransferase KW - Fasting glucose level KW - Gamma-glutamyl transpeptidase KW - Hepatorenal ultrasonographic index KW - High density lipoprotein and low density lipoprotein cholesterol KW - Homeostatic model assessment insulin resistance test KW - Non alcoholic fatty liver disease KW - Silymarin KW - Steato test KW - Total cholesterol SP - 109 EP - 13 JF - World journal of hepatology JO - World J Hepatol VL - 5 IS - 3 N2 - AIM: This study was undertaken to evaluate the hepatic effects of silybum marianum on non alcoholic fatty liver disease (NAFLD). METHODS: In 72 patients affected by NAFLD, main metabolic, hepatic and anti-inflammatory parameters were assayed after 3 mo of a restricted diet and before silymarin treatment (twice a day orally). The brightness of liver echography texture (hepatorenal ratio brightness) was also defined at same time. These evaluations were repeated after 6 mo of treatment. RESULTS: Serum levels of some metabolic and anti-inflammatory data nonsignificantly lowered after 6 mo of silymarin. On the contrary, Steato test, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase were significantly (P < 0.001) reduced. Instead, the AST/ALT ratio unchanged. Finally, the hepatorenal brightness ratio, as an index of hepatic steatosis, significantly (P < 0.05) dropped. CONCLUSION: The obtained results indicate that silymarin appears to be effective to reduce the biochemical, inflammatory and ultrasonic indices of hepatic steatosis. Some parameters indicative of early stage of atherosclerosis were also lowered. SN - 1948-5182 UR - https://www.unboundmedicine.com/medline/citation/23556042/full_citation L2 - http://www.wjgnet.com/1948-5182/full/v5/i3/109.htm DB - PRIME DP - Unbound Medicine ER -